Introduction
============

Estrogen receptors (ER), one of the family of nuclear transcription factors, are responsible for mediating the effects of steroids on many necessary functions such as cellular homeostasis, proliferation, development, reproduction, and gene expression ([@B1], [@B2]). ER genes including ER-α and ER-β are encoded by genes that are found on two different chromosomes: ESR1 located on chromosome 6q25.1 ([@B3]) and ESR2 located on 14q23.2 ([@B4]).

Genetic variation of the ESR genes could potentially lead to ESRs with altered binding kinetics that can adversely affect cellular metabolism ([@B5]). RNA stability of the ESR2 transcript is also explored to be affected by ESR2 rs4986938 polymorphism located in the 3'untranslated region of the gene ([@B6]). As one of the most common form of genetic variation in ESR2, rs4986938 polymorphism has been investigated in numerous studies to evaluate the association with cancer risk in multiple cancers. However, the results remained controversial.

An earlier meta-analysis reported that ESR2 rs4986938 was associated with the risk of breast cancer (BC) ([@B7]). ESR2 rs4986938 polymorphism was not significantly associated with prostate cancer (PCA) risk, either by allelic or genotypic frequencies ([@B8]). A research from Japan discovered that ESR2 rs4986938 were associated with significantly decreased risk of PCA ([@B9]). In addition, no significant differences in genotype frequencies for ESR2 rs4986938 were observed between endometrial cancer cases and controls ([@B5]). More recently, several new studies have also reported an association between ESR2 rs4986938 and cancer risk ([@B9]--[@B11]).

Owing to the inconsistent and inconclusive results found in the literature, the aim of the present meta-analysis was to provide exhaustive evidence to evaluate the effect of ESR2 rs4986938 on cancer risk. The subgroup analysis regarding ethnicity and cancer type were conducted to further analyze.

Methods
=======

Literature search
-----------------

We searched the PubMed, EMBASE, Cochrane library databases for relevant articles up to March 30, 2018, with the following terms: ("variants" or "polymorphisms" or "genetic polymorphism" or "single nucleotide polymorphism" or "SNP") and ("estrogen receptors beta" or "estrogen receptor 2" or "ERbetacx" or "ESR2") and ("tumors" or "neoplasm" or "cancer" or "carcinoma"). We had no limitations in language. Articles derived from these searches and related references cited in these articles were also reviewed.

Inclusion/exclusion criteria
----------------------------

The inclusion criteria of eligible studies were as follows: (a) prospective cohort study or case-control study; (b) the studies assessed the association between ESR2 rs4986938 and cancer risk; (c) detailed genotyping data were provided; (d) cancer cases were histologically diagnosed and confirmed.

The exclusion criteria of eligible studies were as follows: (a) duplicate studies; (b) studies with insufficient genotyping data; (c) studies include case-only; (d) not related to ESR2 rs4986938 polymorphisms and cancer risk.

Data extraction
---------------

Two reviewers (Zhaofang Li and Xiaoli Yang) independently extracted data and reached consensus regarding all the items. If controversy appeared, the third researcher (Rongqiang Zhang) participated in the discussion to resolve the issue. The extracted data included the first author, publication year, country, ethnicity, cancer type, genotyping method, source of controls, sample size, *P* value for HWE and genotype distributions in cases and controls.

Assessment of methodology quality
---------------------------------

The quality of the selected studies was accessed independently according to the Newcastle-Ottawa Scale (NOS). The quality score of the assessment scale was calculated by group selection, comparability and evaluation of exposure or outcome. The scores ranged from 0 to 10 and those with scores ≥6 were considered "high-quality" studies. Any discrepancies in the evaluation were settled by the third researcher (Rongqiang Zhang).

Statistical analysis
--------------------

The strength of associations between SNPs rs4986938 in ESR2 and cancer risk was analyzed by odds ratios (ORs) with 95% confidence intervals (CIs) in additive (A vs. G), dominant (AA+AG vs. GG), recessive (AA vs. AG+GG), heterozygous (AG vs GG) and homozygous (AA vs GG) models. Heterogeneity analysis was conducted using the Cochran's Q test and I2 statistics. In any case *P*\<0.10 was considered with significant heterogeneity. A random-effects model was applied when the heterogeneity was significant; otherwise, fixed-effect model was selected. Sensitivity analysis was conducted to evaluate the reliability and stability of the results by omitting one study at a time and calculating the effect size. Publication bias was accessed by the funnel plots and further performed by Egger's test and Begg's test. All tests carried out in the present report were two-tailed and *P* ≤ 0.05 was considered to be statistically significant. Data were performed using the Stata software (version 12.0; StataCorp LP, College Station, TX, USA) and RevMan software (version 5.3; The Nordic Cochrane Centre, Copenhagen, Denmark).

Results
=======

Study selection and characteristics
-----------------------------------

A total of 210 publications were identified through the literature search. After removing the duplicate articles, 178 articles are still available for subsequent evaluation.

Another 111 articles containing 32 reviews and/or meta-analysis and 79 irrelevant articles were excluded after screening the titles and abstracts. Finally, 20 articles were included in the present study after reading in greater detail ([Fig. 1](#F1){ref-type="fig"}). A total of 23 studies from 20 papers including 24,334 cases and 31,707 controls met the inclusion criteria in the meta-analysis, 2 were cohort studies and the other 21 studies were case-control studies. The rs4986938 polymorphisms were in HWE for all studies. Among the 23 studies, 8 were conducted in USA (8, 12--16), 3 in Japan ([@B9], [@B17]), 2 in Sweden ([@B6], [@B18]) and Germany ([@B19], [@B20]), and 1 each in Tunisia ([@B10]), Brazil ([@B11]), Singapore ([@B21]), Iran ([@B22]), China ([@B23]), Australia ([@B5]), France ([@B24]) and India ([@B25]).

![The flow diagram of identification for studies included](IJPH-48-784-g001){#F1}

The cancer types analyzed in these studies were breast cancer (BC); prostate cancer (PCA); lung cancer (LC); colorectal adenoma (CRA); biliary tract cancers (BTC); and endometrial cancer (EC). The characteristics of the eligible studies are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Characteristics of the eligible studies

  ***Study***         ***Year***   ***Country***    ***Ethnicity***   ***Cancer type***   ***Genotyping method***   ***Control Source***   ***case/control***   ***Quality score***
  ------------------- ------------ ---------------- ----------------- ------------------- ------------------------- ---------------------- -------------------- ---------------------
  Ghali, R.M.         2018         Tunisia          African           BC                  TaqMan                    HB+PB                  207/284              H
  Rezende, L.M.       2017         Brazil           Caucasian         BC                  RFLP-PCR                  NA                     253/257              H
  Lu, X.              2015         Japan            Asian             PCA                 TaqMan                    HB                     352/352              L
  Lim, W.             2012         Singapore        Asian             LC                  TaqMan                    HB                     559/988              H
  Safarinejad, M.R.   2012         Iran             Asian             PCA                 PCR-RFLP                  PB                     162/324              H
  Levine, A.J.        2012         American         Mixed race        CRA                 Illumina's bead array     HB                     655/696              L
  Paulus, J.K.        2011         American         Mixed race        LC                  TaqMan                    HB+PB                  1021/826             H
  Sainz.              2011         Germany          Caucasian         CRC                 PCR-ARMS                  HB                     1752/1774            H
  Su, M.C.G.          2010         Germany          Caucasian         BC                  Mass ARRAY                PB                     3149/5489            H
  Park, S.K.          2010         China            Asian             BTC                 TaqMan                    PB                     411/786              H
  Ashton, K.A.        2009         Australia        Caucasian         EC                  RFLP-PCR                  PB                     191/291              H
  Iwasaki, M.1.       2009         Japan            Asian             BC                  TaqMan                    HB                     388/388              H
  Iwasaki, M.2.       2009         Japan            Caucasian         BC                  TaqMan                    HB                     458/458              H
  Nicolaiew.          2009         France           Caucasian         PCA                 DHPLC                     HB                     286/285              L
  Chae, Y.K.          2009         American         Caucasian         PCA                 TaqMan                    PB                     269/440              H
  Surekha, D.         2009         India            Asian             BC                  RFLP-PCR                  HB                     250/250              L
  Cox, D.G.           2008         American         Caucasian         BC                  TaqMan                    PB                     5789/7761            H
  Chen.1.             2007         American         African           PCA                 TaqMan                    PB                     773/961              H
  Chen.2.             2007         American         Asian             PCA                 TaqMan                    PB                     459/471              H
  Chen.3.             2007         USA and Europe   Caucasian         PCA                 TaqMan                    PB                     5917/6551            H
  Gallicchio, L.      2006         American         Caucasian         BC                  TaqMan                    PB                     91/1347              H
  Maguire, P.         2005         Sweden           Caucasian         BC                  Pyrosequencing            HB                     723/480              L
  Forsti, A.          2003         Sweden           Caucasian         BC                  RFLP-PCR                  PB                     219/248              H

BC: breast cancer; PCA: prostate cancer; LC: lung cancer; CRA: colorectal adenoma; BTC: biliary tract cancers; EC: endometrial cancer

###### 

ESR2 rs4986938 polymorphism genotype distribution and allele frequency in cases and controls

  ***Study***         ***Year***   ***Case***   ***Control***                                     
  ------------------- ------------ ------------ --------------- ------ ----- ------ ------ ------ ------
  Ghali, R.M.         2018         201          55              99     47    283    94     120    69
  Rezende, L.M.       2017         257          97              129    31    253    109    115    29
  Lu, X.              2015         352          280             67     5     352    254    90     8
  Lim, W.             2012         544          446             95     3     964    807    148    9
  Safarinejad, M.R.   2012         162          81              76     5     324    159    124    41
  Levine, A.J.        2012         648          322             257    69    683    311    294    78
  Paulus, J.K         2011         1021         378             485    155   826    303    394    129
  Sainz.              2011         1752         665             825    262   1774   695    815    264
  Su, M.C.G.          2010         3140         1277            1431   432   5478   2169   2557   752
  Park, S.K.          2010         302          11              94     197   772    13     170    589
  Ashton, K.A.        2009         188          87              78     23    286    116    128    42
  Iwasaki, M.1.       2009         388          289             94     5     388    281    102    5
  Iwasaki, M.2.       2009         458          228             180    50    458    236    171    51
  Nicolaiew.          2009         286          138             100    48    285    122    116    47
  Chae, Y.K.          2009         219          81              105    33    370    134    185    51
  Surekha, D.         2009         248          21              95     132   249    9      81     159
  Cox, D.G.           2008         5600         2513            2382   705   7517   3229   3304   984
  Chen.1.             2007         773          408             300    65    961    538    360    63
  Chen.2.             2007         459          315             131    13    471    346    122    3
  Chen.3.             2007         5917         2274            2739   904   6551   2481   3039   1031
  Gallicchio, L.      2006         88           26              43     19    1272   470    612    190
  Maguire, P.         2005         696          298             315    83    421    175    190    56
  Forsti, A.          2003         219          95              99     25    238    105    103    30

PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; PB: population based; HB: hospital-based; H: high-quality; L: low-quality; HWE: Hardy-Weinberg equilibrium; HWE (*P*) = \>0.05

Association between rs4986938 in ESR2 and cancer risk
-----------------------------------------------------

No significant association was detected between the rs4986938 polymorphism and cancer risk in the additive model (A compared with G: OR=0.97, 95% CI=0.92--1.02, *P*=0.20), dominant model (AA+AG compared with GG: OR=0.96, 95% CI=0.93--1.03, *P*=1.00), recessive model (AA compared with AG + GG: OR=0.94, 95% CI=0.86--1.03, *P*=0.18), heterozygous model (AG compared with GG: OR=0.97, 95% CI=0.94--1.01, *P*=0.14), and homozygous model (AA compared with GG: OR=0.96, 95% CI=0.87--1.06, *P*=0.39, [Table 3](#T3){ref-type="table"}). The Forest plot of cancer risk associated with rs4986938 was shown in [Fig. 2](#F2){ref-type="fig"}.

###### 

Meta-analysis of the association between rs4986938 polymorphism and cancer risk. OR: odds ratio; CI: confidence intervals; N: number of included studies; R: random-effect model; F: fixed-effect method

  ***Genetic models***            ***N***   ***Test of association***   ***Model***   ***Test of heterogeneity***   ***(Egger) P-value***        
  ------------------------------- --------- --------------------------- ------------- ----------------------------- ----------------------- ---- -------
  Allelic model (A vs. G)         23        0.97 (0.92,1.02)            0.20          R                             0.0007                  55   0.746
  Caucasian                       13        0.97 (0.95,1.00)            0.07          F                             0.49                    0    
  Asian                           8         0.85 (0.69,1.04)            0.11          R                             0.0003                  74   
  African                         3         1.13 (0.99,1.28)            0.07          F                             0.75                    0    
  Breast cancer                   10        0.97 (0.93,1.00)            0.06          F                             0.09                    40   
  Prostate cancer                 7         1.00 (0.91,1.11)            0.94          R                             0.01                    63   
  Lung cancer                     2         1.01 (0.90,1.14)            0.88          F                             0.53                    0    
  Dominant model (AA+AG vs GG)    23        0.96 (0.93,1.03)            1.00          R                             \<0.000001              71   0.729
  Caucasian                       13        0.95 (0.90,1.00)            0.04          F                             0.47                    0    
  Asian                           8         0.88 (0.70,1.10)            0.26          R                             0.02                    59   
  African                         3         1.16 (0.98,1.38)            0.08          F                             0.60                    0    
  Breast cancer                   10        0.95 (0.91,1.00)            0.07          F                             0.14                    33   
  Prostate cancer                 7         1.00 (0.95,1.06)            0.92          F                             0.10                    44   
  Lung cancer                     2         1.03 (0.88,1.20)            0.72          F                             0.43                    0    
  Recessive model (AA vs AG+GG)   23        0.94 (0.86,1.03)            0.18          R                             0.009                   46   0.597
  Caucasian                       13        0.98 (0.92,1.03)            0.41          F                             0.95                    0    
  Asian                           8         0.70 (0.46,1.05)            0.09          R                             0.02                    56   
  African                         3         1.14 (0.87,1.50)            0.34          F                             0.25                    23   
  Breast cancer                   10        0.96 (0.89,1.03)            0.29          F                             0.45                    0    
  Prostate cancer                 7         1.00 (0.79,1.28)            0.97          R                             0.005                   68   
  Lung cancer                     2         0.97 (0.76,1.24)            0.80          F                             0.45                    0    
  Heterozygote model (AG vs GG)   23        0.97 (0.94,1.01)            0.14          F                             0.20                    19   0.662
  Caucasian                       13        0.96 (0.93,1.01)            0.09          F                             0.58                    0    
  Asian                           8         0.98 (0.85,1.12)            0.77          F                             0.10                    41   
  African                         3         1.14 (0.95,1.37)            0.15          F                             0.44                    0    
  Breast cancer                   10        0.96 (0.91,1.01)            0.10          F                             0.29                    17   
  Prostate cancer                 7         1.01 (0.95,1.07)            0.83          F                             0.21                    28   
  Lung cancer                     2         1.04 (0.88,1.23)            0.62          F                             0.36                    0    
  Homozygote model (AA vs GG)     23        0.96 (0.87,1.06)            0.39          R                             0.02                    41   0.627
  Caucasian                       13        0.96 (0.90,1.02)            0.18          F                             0.81                    0    
  Asian                           8         0.65 (0.35,1.20)            0.17          R                             0.01                    61   
  African                         3         1.29 (0.96,1.73)            0.10          F                             0.62                    0    
  Breast cancer                   10        0.95 (0.88,1.03)            0.20          F                             0.22                    24   
  Prostate cancer                 7         1.01 (0.79,1.31)            0.92          R                             0.005                   68   
  Lung cancer                     2         0.96 (0.73,1.26)            0.76          F                             0.48                    0    

![Forest plot of cancer risk associated with rs4986938. Note: (A) Allelic model, (B) dominant model, (C) recessive model, (D) heterozygous model, (E) homozygous model](IJPH-48-784-g002){#F2}

Subgroup analysis
-----------------

Due to the existence of heterogeneity, analysis of stratification was performed based on ethnicity and cancer type. In the subgroup analysis based on ethnicity, 13 Caucasian studies, 8 Asian studies and 3 African studies found no significant association between rs4986938 in ESR2 and cancer risk in any genetic model ([Table 3](#T3){ref-type="table"}).

In the stratified analysis by cancer type, 10 studies were used to evaluate the relationship between ESR2 rs4986938 polymorphism and BC risk. No significant association was detected between the rs4986938 polymorphism and breast cancer risk in any genetic model ([Fig. 3](#F3){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Meanwhile, no significant association was detected between the rs4986938 polymorphism and PCA risk in any genetic model ([Fig. 4](#F4){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

![Forest plots of ORs for the association between ESR2 rs4986938 and BC. Note: (A) Allelic model, (B) dominant model, (C) recessive model, (D) heterozygous model, (E) homozygous model](IJPH-48-784-g003){#F3}

![Forest plots of ORs for the association between ESR2 rs4986938 and PCA. Note: (A) Allelic model, (B) dominant model, (C) recessive model, (D) heterozygous model, (E) homozygous model](IJPH-48-784-g004){#F4}

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was performed to explore the influence of a single study on the overall risk estimated by removing one study at a time. The ORs were not altered significantly ([Fig. 5](#F5){ref-type="fig"}).

![Sensitivity analyses of ESR2 rs4986938 in five genetic models. Note: (A) Allelic model, (B) dominant model, (C) recessive model, (D) heterozygous model, (E) homozygous model](IJPH-48-784-g005){#F5}

Begg's and Egger's tests were conducted to evaluate the publication bias. The shape of the funnel plot did not reveal any obvious asymmetry ([Fig. 6](#F6){ref-type="fig"}). The *P* values for the Egger's test are shown in [Table 3](#T3){ref-type="table"}.

![Results of Begg's tests in five genetic models. Note: (A) Allelic model, (B) dominant model, (C) recessive model, (D) heterozygous model, (E) homozygous model](IJPH-48-784-g006){#F6}

Discussion
==========

Estrogens could influence many physiological processes in mammals including reproduction, cardiovascular health, bone integrity, cognition, and behavior ([@B26]). In many diseases, estrogen mediates its effects through the estrogen receptor (ER), which serves as the basis for many therapeutic interventions ([@B26]). Rs4986938 of ESR2 has been investigated in many types of cancer. In the present meta-analysis, we systematically analyzed the association between ESR2 rs4986938 and cancer risk. Our results showed that there was no association between ESR2 rs4986938 and cancer risk in all genetic models. In the subgroup analysis based on ethnicity, results showed that Caucasian, Asian and African studies found no significant association between rs4986938 in ESR2 and cancer risk in any genetic model. Meanwhile, no significant association was detected between the rs4986938 polymorphism and the risk of BC and PCA in any genetic model.

Previous meta-analysis studies have been conducted to elucidate the association between the rs4986938 polymorphism and the risk of cancer. In a previous meta-analysis ([@B7]), including 22833 cases and 30319 controls, ESR2 rs4986938 was likely to be related to breast cancer risk, and only contained one type of tumor. In another meta-analysis ([@B27]), including 22833 cases and 30319 controls, results showed that ESR2 rs4986938 polymorphism was associated with decreased breast cancer and ethnicity subgroup analysis observed a decreased risk in both Asian and Caucasian descendent. Owing to the inconsistent and inconclusive results found in previous meta-analysis, the need for additional studies examining the effect of ESR2 rs4986938 on cancer risk seems of vital importance. Besides, our analysis included relevant studies published during the transition period since the previous meta-analysis were carried out. This may be the reason for the inconsistent results. Moreover, we included Africans in our meta-analysis with BC to discover the association between ESR2 rs4986938 and BC which other meta-analysis didn't. To the best of our knowledge, this is the largest and most comprehensive meta-analysis of 23 studies including 24,334 cases and 31,707 controls to determine the association between ESR2 rs4986938 and risk of cancer.

To determine the influence of population stratification, all the data were divided into 3 subgroups: Caucasian, Asian and African. Results showed that polymorphism of rs4986938 had no association with cancer risk in Caucasian, Asian and African subgroup. Our combined analysis was in line with Xia's ([@B28]) analysis that no significant association was detected between the rs4986938 polymorphism and cancer risk. However, due to the existence of heterogeneity, the negative result of the association should be interpreted carefully. Besides, larger sample sizes of studies are needed to confirm the results.

BC is the leading cancer in females worldwide, and the second cause of death among women ([@B28]). In the subgroup meta-analysis under cancer types, no significant association was found between ESR2 rs4986938 variant and BC. Our conclusion was different from another study that concluded SNP rs4986938 might be associated with BC ([@B7]). The present meta-analysis contained 2 updated literatures which coincide with our conclusion ([@B10], [@B11]). Besides, 6 studies published previously also observed no significant association between these gene polymorphisms and susceptibility to BC ( [@B10], [@B11], [@B14], [@B29]--[@B31]). It is likely that other genetic and environmental factors had influenced BC development ([@B32]).

As regarded to the other cancers, no significant association was found between rs4986938 and PCA. ESR2 is regulated by AR and interacts with ESR1 to regulate prostate carcinogenesis through the modulation of genes involved in cell proliferation and apoptosis ([@B16]). However, the associations between ESR2 rs4986938 and PCA have been inconclusive. We pooled the data of 7 studies containing 9634 cases and 10803 controls to clarify the association of ESR2 rs4986938 and prostate cancer. The previous meta-analyses also support our findings ([@B26]).

Several limitations in our study should be mentioned. First, owning to the small sample of African data, the effects of rs4986938 on African populations need to be investigated in large scale and well-designed studies. In addition, the researches about the association of rs4986938 polymorphisms with other cancers are still a relatively emerging field which made it impossible to perform subgroup analysis. Lastly, as positive results are more likely to be published than negative results, it was unavoidable that publication bias lead to the overestimation of effects in meta-analyses.

Conclusion
==========

We systematically reviewed the relationship between rs4986938 polymorphisms and overall cancer risk. We found no evidence of an association between rs4986938 and the risk of overall cancer.
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